Oklahoma 2023 Regular Session

Oklahoma Senate Bill SB712

Introduced
2/6/23  
Refer
2/7/23  
Report Pass
2/23/23  
Refer
2/23/23  
Report Pass
3/1/23  
Engrossed
3/9/23  
Refer
3/29/23  
Report Pass
4/6/23  
Enrolled
4/20/23  
Vetoed
4/26/23  
Override
5/25/23  

Caption

Hospitals; requiring Department of Mental Health and Substance Abuse Services to distribute emergency opioid antagonists to hospitals; requiring hospitals to distribute emergency opioid antagonist to certain persons upon discharge except under certain conditions; granting certain immunities. Effective date.

Impact

The implementation of SB712 represents a significant shift in how hospitals are expected to respond to cases of opioid use issues and aligns with public health goals to mitigate the dangers posed by opioids. By ensuring that patients leave the hospital with emergency opioid antagonists, the bill aims to enhance the chances of survival for individuals at risk of overdose. Furthermore, health benefit plans and the state Medicaid program are required to reimburse hospitals for the distribution of these antagonists, ensuring financial support for healthcare facilities engaging in this public health measure.

Summary

SB712 is a legislative bill aimed at addressing the opioid crisis by requiring hospitals to distribute emergency opioid antagonists, such as naloxone, to patients upon discharge in certain circumstances. The bill mandates that, subject to conditions, hospitals must provide two doses of an emergency opioid antagonist to individuals presenting with an opioid overdose, opioid use disorder, or other adverse effects related to opioid use. This initiative is part of the broader effort to reduce opioid-related fatalities and promote harm reduction strategies. The bill will become effective on November 1, 2023.

Sentiment

Overall, sentiment toward SB712 appears to be supportive, particularly among public health advocates concerned with the opioid epidemic. Proponents argue that the bill will save lives and provide critical resources to individuals at risk. However, there may be concerns regarding the adequacy of funding and resources for hospitals to effectively implement the new requirements. Additionally, discussions may arise about the allocation of emergency opioid antagonists and whether all hospitals will have equal access to these resources, which could impact the effectiveness of the bill in achieving its goals.

Contention

While there is broad support for the core objectives of SB712, discussions around the specifics of implementation, including the distribution process and responsibilities of hospitals, highlighted potential points of contention. Critics may argue that the bill places additional burdens on hospitals without providing sufficient support or guidance. Concerns might also be raised regarding ensuring that all patients, regardless of their insurance status, receive equitable access to emergency opioid antagonists and associated educational resources about opioid use disorder treatment.

Companion Bills

No companion bills found.

Similar Bills

MI HB5077

Health: pharmaceuticals; distribution of naloxone under the administration of opioid antagonist act to any individual; provide for. Amends title & secs. 103 & 107 of 2019 PA 39 (MCL 15.673 & 15.677) & adds sec. 106.

MI HB4366

Health: pharmaceuticals; distribution of naloxone under the administration of opioid antagonist act to any individual; provide for. Amends title & secs. 103 & 107 of 2019 PA 39 (MCL 15.673 & 15.677) & adds sec. 106. TIE BAR WITH: HB 4365'23

MS SB2336

Prevention of overdoses; authorize administration of opioid antagonists by certain persons, provide immunity to.

MS SB2442

Emergency Response and Overdose Prevention Act; amend to expand the distribution and use of opioid antagonists.

MS HB1137

Opioid antagonists; authorize community organizations and others to receive and administer.

MT SB503

Allow use of expired opioid antagonists

HI HB2253

Relating To Health.

CA SB472

Pupil health: opioid overdose reversal medication.